Message

Modalis is a biotechnology company with the objective of developing therapeutics through the use of pioneering technologies, including gene therapy and genome editing. Headquartered in Japan, we conduct our business operations from our research and development base in Greater Boston, Massachusetts, USA, the global hub for biotechnology and pharmaceuticals.

Our CRISPR-GNDM® technology is a novel drug discovery platform that controls gene expression by manipulating epigenetic switches based on CRISPR, the most advanced genome editing technology.

By leveraging the power of CRISPR-GNDM® technology, we are poised to make significant strides in the fight against genetic diseases. The majority of genetic diseases are rare, affecting a limited number of patients, which presents a significant challenge in developing effective treatments. Currently, there are no approved treatments for the majority of these diseases.

However, we believe that this new technology will overcome the limitations of traditional methods, making it possible to provide treatments for diseases that have previously lacked effective solutions.